ARMISTICE CAPITAL LLC 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 9:38 pm Sale | 2025-12-31 | 13G | Travere Therapeutics, Inc. TVTX | ARMISTICE CAPITAL LLC | 3,763,891 4.210% | -2,960,109 (-44.02%) | Filing |
| 2025-11-14 6:28 pm Sale | 2025-09-30 | 13G | Travere Therapeutics, Inc. TVTX | ARMISTICE CAPITAL LLC | 6,724,000 7.520% | -2,148,000 (-24.21%) | Filing |
| 2025-05-15 3:13 pm Purchase | 2025-03-31 | 13G | Travere Therapeutics, Inc. TVTX | ARMISTICE CAPITAL LLC | 8,872,000 9.990% | 1,514,000 (+20.58%) | Filing |
| 2025-02-14 5:22 pm Purchase | 2024-12-31 | 13G | Travere Therapeutics, Inc. TVTX | ARMISTICE CAPITAL LLC | 7,358,000 9.620% | 7,358,000 (New Position) | Filing |